In Russia, the acute ischemic stroke (AIS) drugs market is experiencing modest but important growth propelled by increasing stroke prevalence among an aging population and rising burden of cardiovascular risk factors like hypertension, diabetes, obesity, and smoking. These demographic shifts contribute to a higher incidence of ischemic stroke, driving demand for effective pharmacological interventions across thrombolytics, antiplatelet agents, anticoagulants, and emerging neuroprotective therapies. The establishment of standardized national clinical guidelines endorsing intravenous thrombolysis within 4.5 hours of symptom onset for patients aged 18–80 provides strong clinical impetus for widespread adoption of tPA‑based treatments
TABLE - Russia Acute Ischemic Stroke Drugs Market Size & Forecast By Drug Class 2021-2033
Drug Class | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Thrombolytics | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Anticoagulant | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Antiplatelet | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Neuroprotective Agent | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis